中国肺癌杂志2019，Vol.22Issue(1)：52-56,5.DOI:10.3779/j.issn.1009-3419.2019.01.10
EGFR-TKI原发性耐药的分子机制及其进展——附2例病例分析
Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI——Analysis of 2 Cases
摘要
Abstract
Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy.However, there are still some patients with sensitive mutations have primary drug resistance.It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism.We present 2 cases of primary drug resistance and analyze the reasons.关键词
肺肿瘤/EGFR-TKI/原发性耐药Key words
Lung neoplasms/EGFR-TKI/Primary resistance引用本文复制引用
刘美蓉,孟凡路,马晴,顾立彦,钟殿胜..EGFR-TKI原发性耐药的分子机制及其进展——附2例病例分析[J].中国肺癌杂志,2019,22(1):52-56,5.基金项目
国家自然科学基金资助项目(No.81572268) （No.81572268）
天津市应用基础及前沿技术研究项目(No.17JCYBJC25500)资助 （No.17JCYBJC25500）
